Movement Alert｜GENSCRIPT BIO Rises 6.04% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY Continues to Boost Sentiment

Market Focus

Yesterday

On August 3, GENSCRIPT BIO rose 6.04% in regular trading, trading at HK$18.76/share, with turnover of HK$54.07 million.

On the news front, the company's associate Legend Biotech previously disclosed that CARVYKTI generated net trade sales of approximately $657 million in the quarter ended June 30, representing a nearly 50% year-over-year increase and sustaining strong growth momentum. The sales data was provided by partner Janssen Biotech under their collaboration and license agreement signed in December 2017.

Additionally, Legend Biotech's investigational in vivo CD19/CD20 dual-target CAR-T therapy LB2501 achieved a 100% objective response rate at the higher dose level in a Phase 1 study in relapsed/refractory B-cell non-Hodgkin lymphoma patients, with no dose-limiting toxicities observed. The combination of robust commercial performance from CARVYKTI and positive pipeline developments has driven sustained upward momentum in the stock price.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1199322433"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1199322433\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1199322433?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199322433","market":"hk","top_or_hot":-1,"title":"Movement Alert｜GENSCRIPT BIO Rises 6.04% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY Continues to Boost Sentiment","media":"Market Focus","content":"<p><p>On August 3, GENSCRIPT BIO rose 6.04% in regular trading, trading at HK$18.76/share, with turnover of HK$54.07 million.</p><p>On the news front, the company's associate Legend Biotech previously disclosed that CARVYKTI generated net trade sales of approximately $657 million in the quarter ended June 30, representing a nearly 50% year-over-year increase and sustaining strong growth momentum. The sales data was provided by partner Janssen Biotech under their collaboration and license agreement signed in December 2017.</p><p>Additionally, Legend Biotech's investigational in vivo CD19/CD20 dual-target CAR-T therapy LB2501 achieved a 100% objective response rate at the higher dose level in a Phase 1 study in relapsed/refractory B-cell non-Hodgkin lymphoma patients, with no dose-limiting toxicities observed. The combination of robust commercial performance from CARVYKTI and positive pipeline developments has driven sustained upward momentum in the stock price.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GENSCRIPT BIO Rises 6.04% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY Continues to Boost Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GENSCRIPT BIO Rises 6.04% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY Continues to Boost Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-03 09:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 3, GENSCRIPT BIO rose 6.04% in regular trading, trading at HK$18.76/share, with turnover of HK$54.07 million.</p><p>On the news front, the company's associate Legend Biotech previously disclosed that CARVYKTI generated net trade sales of approximately $657 million in the quarter ended June 30, representing a nearly 50% year-over-year increase and sustaining strong growth momentum. The sales data was provided by partner Janssen Biotech under their collaboration and license agreement signed in December 2017.</p><p>Additionally, Legend Biotech's investigational in vivo CD19/CD20 dual-target CAR-T therapy LB2501 achieved a 100% objective response rate at the higher dose level in a Phase 1 study in relapsed/refractory B-cell non-Hodgkin lymphoma patients, with no dose-limiting toxicities observed. The combination of robust commercial performance from CARVYKTI and positive pipeline developments has driven sustained upward momentum in the stock price.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1199322433","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199322433","pubTimestamp":1785720831,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 3, GENSCRIPT BIO rose 6.04% in regular trading, trading at HK$18.76/share, with turnover of HK$54.07 million.On the news front, the company's associate Legend Biotech previously disclosed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"走势提醒|金斯瑞生物常规交易上涨6.04%，CARVYKTI第二季度销售额同比飙升近50%，继续提振市场情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"On August 3, GENSCRIPT BIO rose 6.04% in regular trading, trading at HK$18.76/share, with turnover of HK$54.07 million.On the news front, the company's associate Legend Biotech previously disclosed that CARVYKTI generated net trade sales of approximately $657 million in the quarter ended June 30, representing a nearly 50% year-over-year increase and sustaining strong growth momentum. The sales data was provided by partner Janssen Biotech under their collaboration and license agreement signed in December 2017.Additionally, Legend Biotech's investigational in vivo CD19/CD20 dual-target CAR-T therapy LB2501 achieved a 100% objective response rate at the higher dose level in a Phase 1 study in relapsed/refractory B-cell non-Hodgkin lymphoma patients, with no dose-limiting toxicities observed. The combination of robust commercial performance from CARVYKTI and positive pipeline developments has driven sustained upward momentum in the stock price.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}